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Background: Stenotrophomonas maltophilia has emerged as an important opportunistic 
pathogen, which causes infections that are often difficult to manage because of the inher-
ent resistance of the pathogen to a variety of antimicrobial agents. In this study, we ana-
lyzed the expressions of SmeABC and SmeDEF and their correlation with antimicrobial 
susceptibility. We also evaluated the genetic relatedness and epidemiological links among 
33 isolates of S. maltophilia.
Methods: In total, 33 S. maltophilia strains were isolated from patients in a tertiary hospital 
in Daejeon. Minimum inhibitory concentrations (MICs) of 11 antimicrobial agents were de-
termined by using agar dilution method and E-test (BioMérieux, France). Real-time PCR 
analysis was performed to evaluate the expression of the Sme efflux systems in the S. 
maltophilia isolates. Additionally, an epidemiological investigation was performed using 
multilocus sequence typing (MLST) assays.
Results: The findings of susceptibility testing showed that the majority of the S. maltophilia 
isolates were resistant to β-lactams and aminoglycosides. Twenty-one clinical isolates over-
expressed SmeABC and showed high resistance to ciprofloxacin. Moreover, a high degree 
of genetic diversity was observed among the S. maltophilia isolates; 3 sequence types (STs) 
and 23 allelic profiles were observed.
Conclusions: The SmeABC efflux pump was associated with multidrug resistance in clini-
cal isolates of S. maltophilia. In particular, SmeABC efflux pumps appear to perform an 
important role in ciprofloxacin resistance of S. maltophilia. The MLST scheme for S. malto-
philia represents a discriminatory typing method with stable markers and is appropriate 
for studying population structures.
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INTRODUCTION
Stenotrophomonas maltophilia is a non-fermentative gram-neg-
ative bacillus found extensively in the environment and has 
emerged as an important nosocomial pathogen [1, 2]. S. malto-
philia causes a variety of nosocomial infections, particularly 
pneumonia and bacteremia in severely debilitated or immuno-
suppressed patients with underlying chronic diseases who are 
admitted to intensive care units. Its infamy is partly attributable 
to its characteristic resistance to most of the currently available 
broad-spectrum antimicrobial agents and partly to its ability to 
rapidly proliferate a multiresistant phenotype [3-5].
  S. maltophilia has high intrinsic resistance to a variety of struc-
turally unrelated antimicrobial agents, including β-lactams, ami-
noglycosides, and quinolones. In part, the resistance of S. malto-
philia to multiple antimicrobial agents can be attributed to lim-Cho HH, et al.
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ited outer membrane permeability and active antimicrobial ef-
flux; 2 Sme efflux systems, SmeABC and SmeDEF, have been 
identified in this organism [6-8]. The mechanisms underlying 
antimicrobial drug resistance in clinical isolates have proven 
problematic in the treatment of S. maltophilia infections. The re-
cently developed multilocus sequence typing (MLST) technique 
appears to be a reliable tool for tracking the source of infection 
and the distribution of pathogens isolated from hospitalized pa-
tients; this technique provides consistent epidemiological data, 
and the results from different laboratories can be compared be-
cause the international databases are easily accessible [9-11].
  The objectives of the present study were to correlate the anti-
microbial resistance patterns of the S. maltophilia isolates with 
their antimicrobial efflux mechanisms and to determine the ge-
netic characteristics of S. maltophilia isolates that are responsi-
ble for their current epidemic status.
METHODS
1. Bacterial isolates and antimicrobial susceptibility tests
In total, 33 consecutive, non-duplicated S. maltophilia isolates 
were obtained from patients in a tertiary hospital in Daejeon, Ko-
rea between January and December 2009. Biochemical profiling 
using conventional methods and the Vitek 2 system (BioMéri-
eux, Hazelwood, MO, USA) for microbial identification were 
used to confirm that the isolates were S. maltophilia.
  In the antimicrobial susceptibility tests, minimum inhibitory 
concentration (MIC) was determined by using the agar dilution 
method and an E-test conducted in accordance with the guide-
lines of the CLSI [12, 13]. The susceptibility of S. maltophilia to 
the following antimicrobial agents was tested: ceftazidime (Hanmi, 
Seoul, Korea), cefepime (Boryung, Seoul, Korea), ticarcillin/cla-
vulanic acid, meropenem, aztreonam, trimethoprim/sulfamethox-
azole (bioMérieux, Marcy I’Etoile, France), amikacin, gentami-
cin, levofloxacin, minocycline (Sigma Chemical Co., St Louis, 
MO, USA), and ciprofloxacin (Fluka, Buchs, Switzerland). Esch-
erichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 
27853 were used for quality control purposes.
2.     Real-time PCR analysis to assess the expression of the 
Sme efflux system
Cell suspensions were prepared and inoculated in brain–heart 
infusion broth (Difco, Cockeysville, MD, USA). After overnight 
culture, total RNA was extracted from the cell suspensions by 
using the TRI REAGENT
® (Montgomery, OH, USA). Additionally, 
20 µL of cDNA was obtained from 5 μg of total RNA by using 
the DiaStar™ RT Kit (SolGent, Daejeon, Korea). The amplifica-
tion mixtures for real-time PCR (20 µL) contained template 
cDNA, 2× SYBR Green Ǎ Master Mix (Applied Biosystems, 
Foster, CA, USA), and primers.
  The sequences of the primers designed for this study were as 
follows: smeB (F: 5′-ACCGCCCAGCTTTCATACAG-3′; R: 5′-GA-
CATGGCCTACCAGGAACAG-3′) and smeF (F: 5′-TCGTCCAG-
GCTGACATTCAA-3′; R: 5′-AACGCGGATCGTGATATCG-3′). The 
primer sequences used for the endogenous control gene were 
rDNA (F: 5′-TGACACTGAGGCACGAAAGC-3′; R: 5′-CATCGTT-
TAGGGCGTGGACTA-3′). Real-time PCR reactions were per-
formed using the StepOne real-time PCR (Applied Biosystems); 
the PCR cycle included the following steps: activation and de-
naturation step for 10 min at 95°C, 40 cycles of 15 sec at 95°C, 
and annealing and extension for 1 min at 60°C. Standard curves 
for the expression levels of smeABC, smeDEF, and rDNA were 
constructed using the expression levels of these genes in S. 
maltophilia ATCC 13637; these standard curves were used as 
calibrators to normalize the relative expression levels of the 
smeB and smeF genes in clinical isolates. Overexpression of the 
Sme efflux system was assessed as described in the study of 
Chang et al. [7].
3. MLST
Genomic DNA was extracted from the clinical isolates by using 
a Genomic DNA Prep Kit (SolGent) and was used as a template. 
PCR was performed using 50 ng of the template DNA (genomic 
DNA), 2.5 μL of 10×Taq buffer, 0.5 μL of 10 mM dNTP mix, 20 
pmol of each primer, and 0.7 U of Taq DNA Polymerase (Sol-
Gent) in a total volume of 25 μL. Internal fragments of 7 house-
keeping genes (atpD, gapA, guaA, mutM, nuoD, ppsA, and 
recA) were amplified in a GeneAmp PCR System 9600 (Perkin-
Elmer Cetus Corp., Norwalk, CT, USA) by using the following 
steps: pre-denaturation of the reaction mixture for 9 min at 95°C; 
30 cycles of 20 sec at 94°C, 1 min at appropriate annealing tem-
perature, and 50 sec at 72°C; and final elongation for 5 min at 
72°C [9]. The amplicons were purified using a PCR Purification 
Kit (SolGent) and sequenced using a BigDye Terminator Cycle 
Sequencing Kit (Applied Biosystems) and an ABI PRISM 3730XL 
DNA Analyzer (Applied Biosystems). The allele number for each 
gene was assigned on the basis of the information in the S. malto-
philia MLST database (http://pubmlst.org/smaltophilia/). A com-
bination of the allelic sequences of the 7 genes yielded the al-
lelic profile for each isolate.Cho HH, et al.
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4. Statistical analysis
The data was analyzed using SPSS ver. 12.0 (SPSS, Inc., Chi-
cago, IL, USA) with Student’s t test. The differences were con-
sidered statistically significant at P<0.05.
RESULTS
1. The pattern of antimicrobial resistance
We tested the susceptibility of 33 clinical isolates of S. maltophilia 
to 11 antimicrobial agents on the basis of the MIC determina-
tions (Table 1). S. maltophilia showed low susceptibility to ce-
fepime (9.1%), meropenem (0%), and aztreonam (3.0%), which 
are members of the β-lactam group; however, it showed rela-
tively high susceptibility to ceftazidime (69.7%). The susceptibil-
ity of the organism to aminoglycosides, namely, amikacin and 
gentamicin, was 6.1%, whereas that for ciprofloxacin (a quino-
lone) was 45.5%. Most of the isolates were susceptible to ticarcil-
lin/clavulanic acid (97.0%), levofloxacin (87.9%), trimethoprim/
sulfamethoxazole (93.9%), and minocycline (97.0%). 
2. Determining the overexpression of smeABC and smeDEF
Real-time PCR analysis was used to assess the overexpression 
of the Sme efflux systems (smeABC and smeDEF), and the re-
sults of the analysis showed overexpression of smeB in 21 (63.6 
%) and smeF in 19 (57.5%) of the 33 clinical isolates. Fifteen 
(45.4%) isolates overexpressed both smeB and smeF (Table 2). 
After analyzing the pattern of antimicrobial resistance and the 
overexpression of Sme efflux systems, the MICs of ciprofloxacin 
(MIC50=4; 6.83-fold increase) and levofloxacin (MIC50=1; 3.60-
fold increase) were found to be significantly higher for the iso-
lates with detectable smeB and/or smeF than for the isolates 
without detectable smeB and/or smeF. Overexpression of the 
SmeABC efflux pump was statistically related to the MICs of cip-
rofloxacin (P=0.033) and levofloxacin (P=0.034). However, the 
overexpression of SmeDEF (CIP, P=0.100; LEV, P=0.162) alone 
and both SmeABC and SmeDEF (CIP, P=0.056; LEV, P=0.064) 
were not related to quinolone resistance. 
3. MLST analysis
In the MLST analysis of the 33 S. maltophilia isolates, 3 sequence 
types (STs) (ST5, ST28, and ST31) and 23 diverse allelic profiles 
were detected (Table 1). The most common form of allelic pro-
file was 19, 5, 14, 8, 5, 26, 4 (4 isolates); the other forms were 
ST31 (3, 4, 24, 7, 7, 22, 7; 2 isolates), ST5 (5, 22, 9, 4, 27, 5, 7; 2 
isolates), 8, 20, 10, 25, 14, 17, 3 (2 isolates), and 2, 13, 42, 20, 
30, 27, 20 (2 isolates). 
  The NJ tree model was chosen for representing the findings 
of the cluster analysis of all 33 S. maltophilia strains (Fig. 1).
DISCUSSION
S. maltophilia was first reported in the early 1970s, and since 
then, it has continued to spread through the 1990s. This spread 
can be attributed to the widespread use of chemotherapy and 
broad-spectrum antimicrobial agents as well as to the adoption 
of highly invasive medical practices [14]. Among the clinically 
important bacteria isolated from major hospitals in Korea, S. 
maltophilia had isolation rates of 1.8% in 1998 and 3.1% in 2005 
and 2006; these isolation rates are indicative of a serious prob-
lem of nosocomial infection [15, 16]. 
  S. maltophilia is intrinsically resistant to multiple antimicrobial 
agents, including β-lactams, aminoglycosides, carbapenems, 
and quinolones; clinical isolates of S. maltophilia frequently ex-
hibit high multidrug resistance. In this study, 33 S. maltophilia 
isolates were found to be highly resistant to β-lactams and ami-
noglycosides; these organisms showed a ciprofloxacin suscepti-
bility rate of 45.5%. According to the findings of a survey con-
ducted in Korea between 2000 and 2003, the rate of ciprofloxa-
cin resistance was approximately 10% [17]. However, in this 
study, the organism showed a significant 3-fold increase in drug 
resistance. 
  Although various mechanisms for antimicrobial drug resis-
tance have been reported in clinical isolates of S. maltophilia 
thus far, little information is available about this species in Ko-
rea. Recently, antimicrobial efflux mechanisms have been in-
creasingly recognized as major factors in the intrinsic and ac-
quired resistance of many significant human pathogens, includ-
ing Pseudomonas aeruginosa and Burkholderia cepacia. In 
particular, antimicrobial efflux systems (including MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, and MexXY-OprM) belonging to the 
resistance-nodulation-division family, which contribute to multi-
drug resistance have been characterized in P. aeruginosa [18-
20]. Additionally, overexpression of the SmeABC and SmeDEF 
efflux pumps in S. maltophilia contributes to intrinsic multidrug 
resistance and plays an important role in the resistance charac-
teristics of clinical isolates. There have been reports that the 
overexpression of the Sme efflux system of S. maltophilia in-
duced resistance to several antimicrobial agents, including 
β-lactams, aminoglycosides, and quinolones [6, 7, 21, 22]. We 
found that the overexpression rates of smeB and smeF were 
63.6% and 57.4%, respectively, in organisms with high resis-
tance to β-lactams and aminoglycosides. A study conducted in Cho HH, et al.
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Taiwan in 2004 indicated that the SmeABC efflux pumps might 
play a role in the ciprofloxacin resistance of S. maltophilia [7]. In 
this study, 21 isolates with smeB, which was detected using real-
time PCR analysis, showed a 6.83-fold and 3.60-fold increase in 
the MICs of ciprofloxacin and levofloxacin, respectively. The MIC 
of ciprofloxacin in our study was 3-fold higher than that in a pre-
vious Taiwanese report (2.16-fold). Thus, we suggest that the 
overexpression of SmeABC was associated with high MIC values 
Table 1. MLST, antimicrobial susceptibility, and mRNA expression studies for the 33 Stenotrophomonas maltophilia isolates
Isolates Allelic profile
MIC (μg/mL)
mRNA 
expression for:
CAZ      FEP      TIM MEM ATM AMK GEN  CIP LEV SXT MIN SmeABC SmeDEF
CNS1 3, 4, 1, 7, 7, 38, 19 8 128  8 >32 >256 >256 >1,024 4 0.5 0.5 <1 + +
CNS2 3, 4, 24, 7, 7, 22, 7 16 48  8 >32 >256 >256 64 1 1 0.25 <1 +
CNS3 5, 22, 9, 4, 27, 5, 7 2 6  8 >32 48 64 16 8 4 0.5 4 + +
CNS4 8, 20, 10, 25, 14, 17, 3 4 128  4 >32 >256 >256 128 4 1 0.5 <1 + +
CNS6 3, 4, 24, 7, 7, 22, 7,  64 32  8 >32 >256 >256 32 4 2 0.5 <1 + +
CNS8 3, 1, 2, 7, 25, 20, 6 8 16  8 >32 >256 >256 128 1.5 1 0.5 <1
CNS9 1, 1, 14, 3, 1, 7, 19 8 48  8 >32 >256 >256 128 1.5 1 0.5 <1
CNS10 2, 13, 42, 20, 30, 27, 20 32 64 256 >32 >256 >256 >1,024 1.5 0.5 0.5 <1 +
CNS11 28, 8, 4, 33, 18, 15, 16 >256 128  4 >32 >256 >256 64 1 0.25 0.5 <1
CNS12 1, 1, 15, 3, 25, 7, 7 8 48 4 >32 >256 >256 32 1.5 1 0.5 <1 + +
CNS13 8, 20, 10, 25, 14, 17, 3 4 64  8 >32 >256 >256 128 64 16 0.75 >16 + +
CNS15 5, 22, 9, 4, 27, 5, 7 4 32  8 >32 >256 64 16 8 2 0.5 <1 + +
CNS16 3, 35, 5, 6, 6, 1, 6 8 6  8 >32 >256 >256 128 1 1 0.5 <1
CNS17 5, 3, 14, 5, 9, 6, 9 2 48  2 >32 >256 >256 32 0.5 0.5 0.25 <1 + +
CNS18 13, 28, 14, 23, 33, 31, 22 4 48  4  >32 >256 >256 >1,024 4 1 0.5 <1 + +
CNS19 20, 25, 10, 9, 29, 2, 15 <1 2  2 >32 4 16 4 0.5 0.25 0.25 <1
CNS20 4, 3, 14, 5, 9, 6, 9 8 48  8 >32 >256 16 4 1 1 0.25 <1 + +
CNS21 5, 22, 9, 6, 27, 6, 7 8 32  4 >32 >256 >256 32 3 1 0.25 <1 + +
CNS22 19, 5, 14, 8, 5, 26, 4 8 48  4 >32 >256 >256 128 1 0.5 0.25 <1 +
CNS24 5, 3, 2, 5, 9, 6, 9 8 32  8 >32 >256 >256 32 1 0.5 0.25 <1
CNS25 4, 3, 2, 5, 9, 6, 9 16 48  2 >32 >256 >256 24 1 0.5 0.5 <1 +
CNS26 19, 5, 14, 8, 5, 26, 4 8 64  8 >32 >256 >256 64 1 0.5 0.5 <1
CNS27 19, 5, 14, 8, 5, 26, 4 4 64  4  >32 >256 >256 64 1 0.5 0.25 <1
CNS28 2, 13, 42, 20, 30, 27, 20 2 64  4  >32 >256 >256 256 3 0.5 0.5 <1 +
CNS29 19, 5, 14, 8, 5, 26, 4 8 48  8 >32 >256 >256 32 0.75 0.5 0.25 <1 +
CNS31 26, 1, 15, 6, 25, 19, 19 16 96  8 >32 >256 >256 32 4 1 0.5 <1 + +
CNS32 21, 8, 10, 33, 18, 15, 16 >256 128  8 >32 >256 >256 16 0.5 1 0.5 <1 +
CNS33 2, 2, 2, 2, 2, 3, 5 4 32  8 >32 >256 >256 32 1 0.5 0.5 <1 + +
CNS35 26, 15, 9, 30, 16, 27, 11 128 96  8 >32 >256 >256 24 8 2 1 2 + +
CNS38 21, 8, 4, 33, 4, 15, 16 >256 96  8 >32 >256 >256 64 4 0.5 >32 <1 + +
CNS39 3, 1, 1, 3, 6, 4, 1 4 16  8 >32 >256 >256 >1,024 8 4 >32 <1 +
CNS41 9, 21, 28, 26, 15, 18, 3 4 64  4  >32 >256 >256 >1,024 6 4 0.5 <1 +
CNS42 21, 5, 4, 17, 21, 23, 11 64 128  4  >32 >256 >256 128 0.75 0.5 0.25 <1 +
Abbreviations: MLST, multilocus sequence typing; MIC, minimum inhibitory concentration; CAZ, ceftazidime; FEP, cefepime; TIM, ticarcillin/clavulanic acid; 
MEM, meropenem; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; MIN, mi-
nocycline.Cho HH, et al.
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for ciprofloxacin (P=0.033) and levofloxacin (P=0.034). How-
ever, the overexpression of SmeDEF (CIP, P=0.100; LEV, P=
0.162) alone and both SmeABC and SmeDEF (CIP, P=0.056; 
LEV, P=0.064) were not related to quinolone resistance.
  MLST for molecular epidemiologic studies of S. maltophilia is 
a recently developed strain-typing system that focuses strictly 
on conserved housekeeping genes. In previous studies in Ko-
rea, this genetic relationship was evaluated using pulsed-filled 
gel electrophoresis (PFGE) after XbaǍ digestion or molecular 
typing by using enterobacterial repetitive intergenic consensus 
(ERIC)-PCR and random amplified polymorphic DNA (RAPD) 
[17, 23]. It is thought that phylogenetic studies of S. maltophilia 
by using MLST will contribute significantly to a new perspective 
on the molecular epidemiology of S. maltophilia. We applied 
MLST analysis to 33 strains and found that most of the strains 
represent 3 STs (ST5, ST28, and ST31) as well as 23 new allelic 
profiles. Similarly, studies in Spain in 2004 and in Korea in 2010 
showed a high degree of genetic diversity among S. maltophilia 
isolates despite their origin in a single hospital [5, 23]. This find-
ing indicates that S. maltophilia has a high potential for environ-
mental distribution. In the S. maltophilia MLST database (http://
www.pubmlst.org/smaltophilia/), 56 STs have been reported thus 
far, of which ST5, ST28, and ST31 have been identified in Korea. 
Database analysis shows that there are considerably fewer STs 
for S. maltophilia isolates than other bacterial isolates. 
  A distinct finding of our study was the relationship between 
quinolone resistance and the overexpression of the SmeABC ef-
flux system. This relationship was also observed in some parts 
of the MLST cluster. The group A and A′ isolates shown in Fig. 1 
were highly resistant to ciprofloxacin and harbored smeB, as 
observed in the real-time PCR analysis. Additionally, the group 
B isolates were highly resistant to ceftazidime and cefepime 
(Fig. 1). A similar relationship exists between the clonal complex 
17 (CC17) and antimicrobial resistance of Enterococcus faecium. 
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Fig. 1. A phylogenetic tree of the concatenated nucleotide sequenc-
es of 7 housekeeping genes (atpD, gapA, guaA, mutM, nuoD, ppsA, 
and recA) of S. maltophilia obtained using the NJ method with Kimu-
ra 2 correction for distance calculations. Group A and A’ isolates 
were highly resistant to ciprofloxacin and overexpressed smeB, and 
Group B isolates were highly resistant to ceftazidime and cefepime.
A
A’
B
Table 2. Correlation between antimicrobial susceptibility and the expression of smeABC and smeDEF in Stenotrophomonas maltophilia
N (%)
MIC50 (μg/mL)
CAZ FEP TIM MEM ATM AMK GEN CIP LEV SXT MIN
smeABC (+) 21 (63.6%) 8 48 8 >32 >256 >256 32 4 1 0.5 <1
smeABC (-) 12 8 48 8 >32 >256 >256 64 1 0.5 0.5 <1
smeDEF (+) 19 (57.5%) 8 48 8 >32 >256 >256 32 4 1 0.5 <1
smeDEF (-) 14 8 48 8 >32 >256 >256 64 1 0.5 0.5 <1
smeABC and smeDEF (+) 15 (45.4%) 8 48 8 >32 >256 >256 32 4 1 0.5 <1
smeABC and smeDEF (-) 8 8 32 8 >32 >256 >256 64 1 0.5 0.5 <1
Abbreviations: MIC, minimum inhibitory concentration; CAZ, ceftazidime; FEP, cefepime; TIM, ticarcillin/clavulanic acid; MEM, meropenem; ATM, aztreo-
nam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; MIN, minocycline.Cho HH, et al.
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CC17 was defined by using an MLST assay and is regarded as 
excellent example of cumulative evolutionary processes. In the 
majority of the E. faecium isolates, CC17 is characterized by am-
picillin and quinolone resistance as well as the presence of a 
putative pathogenicity island, including the esp gene [24, 25]. 
  The incidence of S. maltophilia infections has increased world-
wide, but only a few studies on this topic have been performed 
in Korea thus far. On the basis of the findings of the MLST as-
says for S. maltophilia, we found that antimicrobial resistance 
correlated with the overexpression of the Sme efflux systems.
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